Abstract
High grade serous (HGS) cancer of the ovary (OC) is a lethal malignancy with advanced stage disease remaining incurable. HGS OC is sensitive to platinum based chemotherapy with complete responses being frequent, but relapses are inevitable, with resistance invariably emerging. Deeper understanding of the pathogenesis of HGS OC with new sequencing techniques shows that aberrations in the BRCA pathway may play a major role. Changes in the homologous recombination pathway and DNA repair may play a role in platinum resistance. This review article describes various approaches that have been studied in the management of chemotherapy resistance in HGS OC including Poly ADPribose polymerase (PARP) inhibition, Wee1 inhibition, epigenetic agents, immunotherapy and angiogenesis targeting agents.
Keywords: Chemotherapy, high grade serous, ovarian, resistance.
Current Cancer Therapy Reviews
Title:Overcoming Chemotherapy Resistance in High Grade Serous Ovarian Cancer
Volume: 12 Issue: 1
Author(s): Raghav Sundar, David Tan, Lim S. Lei and Whay-Kuang Chia
Affiliation:
Keywords: Chemotherapy, high grade serous, ovarian, resistance.
Abstract: High grade serous (HGS) cancer of the ovary (OC) is a lethal malignancy with advanced stage disease remaining incurable. HGS OC is sensitive to platinum based chemotherapy with complete responses being frequent, but relapses are inevitable, with resistance invariably emerging. Deeper understanding of the pathogenesis of HGS OC with new sequencing techniques shows that aberrations in the BRCA pathway may play a major role. Changes in the homologous recombination pathway and DNA repair may play a role in platinum resistance. This review article describes various approaches that have been studied in the management of chemotherapy resistance in HGS OC including Poly ADPribose polymerase (PARP) inhibition, Wee1 inhibition, epigenetic agents, immunotherapy and angiogenesis targeting agents.
Export Options
About this article
Cite this article as:
Sundar Raghav, Tan David, Lei S. Lim and Chia Whay-Kuang, Overcoming Chemotherapy Resistance in High Grade Serous Ovarian Cancer, Current Cancer Therapy Reviews 2016; 12 (1) . https://dx.doi.org/10.2174/1573394712666160609121238
DOI https://dx.doi.org/10.2174/1573394712666160609121238 |
Print ISSN 1573-3947 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6301 |
Call for Papers in Thematic Issues
Current progress in Protein Degradation and Cancer Therapy
argeted Protein Degradation is gaining momentum in cancer therapy, it facilitate targeting undruggable proteins, it overcome cancer resistance and avoid undesirable side effects. Thus small molecules degraders have emerged as novel therapeutic strategy. Targeted protein degradation (TPD), the process of eliminating a protein of interest hold a great promise for ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Safety of the Thrombopoiesis-Stimulating Agents for the Treatment of Immune Thrombocytopenia
Current Drug Safety The Impact of Thrombopoietin on Clinical Practice
Current Pharmaceutical Design STAT3: A Molecular Target for Cancer Whose Time Has Come
Current Signal Transduction Therapy Pharmacoepigenomics: An Interplay of Epigenetic Modulation of Drug Response and Modulation of the Epigenome by Drugs
Current Pharmaceutical Design Lipid-Based Nanoparticulate Systems for the Delivery of Anti-Cancer Drug Cocktails: Implications on Pharmacokinetics and Drug Toxicities
Current Drug Metabolism Rheumatic Manifestations in Malignancy
Current Rheumatology Reviews VS-5584 Inhibits Human Osteosarcoma Cells Growth by Induction of G1- phase Arrest through Regulating PI3K/mTOR and MAPK Pathways
Current Cancer Drug Targets Pharmacokinetics-Pharmacology Disconnection of Herbal Medicines and its Potential Solutions with Cellular Pharmacokinetic-Pharmacodynamic Strategy
Current Drug Metabolism <i>Nigella sativa</i> – A Functional Spice From A Pharaoh’s Tomb to Modern Healthcare
The Natural Products Journal Inflammation and Cancer: In Medio Stat Nano
Current Medicinal Chemistry Interlinking of Hypoxia and Estrogen in Thyroid Cancer Progression
Current Medicinal Chemistry Anti-cancer and Anti-angiogenic Properties of Various Natural Pentacyclic Tri-terpenoids and Some of their Chemical Derivatives
Current Organic Chemistry The Role of Mass Spectrometry in the “Omics” Era
Current Organic Chemistry The Human Glioma-Associated Oncogene Homolog 1 (GLI1) Family of Transcription Factors in Gene Regulation and Diseases
Current Genomics Medicinal Compound Celastrol As a Potential Clinical Anticancer Drug: Lessons Learned From Preclinical Studies
Clinical Cancer Drugs Interleukin-6/interleukin-6 Receptor Pathway as a New Therapy Target in Epithelial Ovarian Cancer
Current Pharmaceutical Design Recent Advances in the Identification of Genetic and Biochemical Components of Breast Cancer Predisposition
Current Genomics YB-1 Protein and Multidrug Resistance of Tumor Cells
Current Signal Transduction Therapy Advances on Magnetic Nanocarriers Based on Natural Polymers
Current Pharmaceutical Design Glycoconjugates of Quinolines: Application in Medicinal Chemistry
Mini-Reviews in Medicinal Chemistry